The present study reports the behavioral, electrophysiological, and neuropathological
effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the …

Background and Purpose A non‐psychoactive phytocannabinoid, cannabidiol (CBD), shows
promising results as an effective potential antiepileptic drug in some forms of refractory …

Epilepsy is a neurological disorder characterized by the presence of seizures and
neuropsychiatric comorbidities. Despite the number of antiepileptic drugs, one-third of …

Objective Epilepsy is a progressive neurological disease characterized by recurrent
seizures and behavioral comorbidities. We investigated the antiseizure effect of cannabidiol …

Cannabidiol (CBD), the main nonpsychotomimetic compound from Cannabis sativa, inhibits
experimental seizures in animal models and alleviates certain types of intractable epilepsies …

Anecdotal reports of the benefits of cannabis and its components in the treatment of epilepsy
have been reported for millennia. However, only recently randomized controlled trial data in …

Abstract The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt)/mechanistic
target of rapamycin (mTOR) signaling pathway has been associated with several …

Cannabidiol (CBD) is a marijuana compound implicated in epilepsy treatment in animal
models and pharmacoresistant patients. However, little is known about chronic CBD …

Plant-derived cannabinoids (phytocannabinoids) are compounds with emerging therapeutic
potential. Early studies suggested that cannabidiol (CBD) has anticonvulsant properties in …

Cannabis sativa has been associated with contradictory effects upon seizure states despite
its medicinal use by numerous people with epilepsy. We have recently shown that the …